STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $1,296,840.00 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 53,500 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were purchased at an average cost of $24.24 per share, with a total value of $1,296,840.00. Following the purchase, the insider now directly owns 10,821,931 shares of the company’s stock, valued at $262,323,607.44. The trade was a 0.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The shares were acquired at an average price of $24.33 per share, with a total value of $559,590.00.

STAAR Surgical Trading Down 0.6 %

STAA opened at $24.82 on Friday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 56.41 and a beta of 0.59. The company’s fifty day moving average price is $28.31 and its two-hundred day moving average price is $34.56. STAAR Surgical has a 1-year low of $23.72 and a 1-year high of $52.68.

Hedge Funds Weigh In On STAAR Surgical

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its stake in shares of STAAR Surgical by 173.5% in the second quarter. SG Americas Securities LLC now owns 9,038 shares of the medical instruments supplier’s stock worth $430,000 after purchasing an additional 5,733 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in STAAR Surgical by 3.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after acquiring an additional 418 shares in the last quarter. Louisiana State Employees Retirement System boosted its holdings in STAAR Surgical by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock worth $1,176,000 after acquiring an additional 500 shares during the last quarter. Slow Capital Inc. lifted its position in shares of STAAR Surgical by 3.1% during the second quarter. Slow Capital Inc. now owns 67,649 shares of the medical instruments supplier’s stock valued at $3,221,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in STAAR Surgical by 1.4% during the second quarter. Bank of New York Mellon Corp now owns 405,222 shares of the medical instruments supplier’s stock worth $19,293,000 after purchasing an additional 5,712 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on STAA shares. Stephens upgraded STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. Finally, Stifel Nicolaus reduced their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and a consensus target price of $42.83.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.